Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
S-FACT TN-1 triple-negative breast cancer neoadjuvant platform trial
jRCT2031240160Active, not recruiting
- Sponsor
- Takeda
- Start
- Jul 2024
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of pembrolizumab, niraparib, carboplatin, paclitaxel, doxorubicin and 1 more in triple-negative breast cancer (TNBC) (2 arms), sponsored by Takeda. Primary endpoints: Pathological complete response and ctDNA clearance proportion. Started Jul 2024; status: active, not recruiting.
02
Drugs
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on jRCT2031240160.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240160.